Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study reported the successful management of cardiac tamponade in a pregnant woman with systemic lupus erythematosus using pericardiocentesis and immunosuppressant therapy, although the patient declined cyclophosphamide treatment.

Most women continued using oral minoxidil for hair loss despite mild to moderate side effects.

In this reported case, a 30-year-old man with a long history of alopecia universalis experienced limited regrowth of eyebrows and eyelashes after six months of deuruxolitinib, despite unchanged scalp hair, suggesting site-specific potential for hair regrowth in challenging cases.

This review discusses recent adult studies on systemic lupus erythematosus treatments and explores their implications for pediatric cases, emphasizing a critical need for more pediatric-focused research.

In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.

In this study, researchers developed a new Supported Ionic Liquid Phase palladium catalyst that showed effectiveness in aminocarbonylation reactions for synthesizing pharmaceutical compounds like CX-546 and a precursor of Finasteride, though results were sensitive to substrate variations and prompted palladium leaching concerns.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

This study suggests that prenatal genetic diagnosis of MELAS syndrome using amniotic cells may not reliably predict fetal outcomes due to phenotypic diversity observed in siblings with similar levels of mutant mtDNA.

This article is a letter to the editor discussing hair graying and loss potentially induced by imatinib mesylate, but it does not provide new research results.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

In this study, nifedipine provided rapid symptomatic relief in most patients with severe recalcitrant perniosis, but some experienced side effects that limited dosage and two patients were lost to follow-up.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This review discusses the potential therapeutic applications of wedelolactone, a compound in Eclipta prostrata, for various chronic human diseases and reports no new clinical results.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

This study found that finasteride significantly inhibits the metabolism of tirilazad to its active metabolites without greatly affecting tirilazad's overall clearance.

This article discusses the potential of oral bicalutamide as a promising treatment for female pattern hair loss and reports no new clinical results.

This study reported that the NUDT15 R139C genetic variant was significantly associated with thiopurine-induced leukocytopenia in Japanese inflammatory bowel disease patients, independent of 6-thioguanine nucleotide levels.

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.

This study found that pulsed doses of prednisolone led to excellent hair growth in 60% of young patients with widespread alopecia areata, with minimal side effects.

This case report describes a patient who developed severe alopecia and a rash after increasing captopril dosage, which resolved upon discontinuing the medication.

This case report describes a 43-year-old man who developed lupus miliaris disseminatus faciei after discontinuation of cyclosporine A post-stem cell transplantation, successfully treated with oral isotretinoin and topical tacrolimus.

This review discusses the potential of using triads of repositioned medicines targeting multiple pathogenic mechanisms to prevent or delay retina degeneration, but reports no new results.

Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.

This study found that the PPARγ modulator NAC-GED-0507-Levo may protect hair follicles from chemotherapy-induced damage, potentially offering a strategy to address irreversible hair loss in cancer patients.

This letter highlights the lack of evidence on managing persistent alopecia induced by chemotherapy and endocrine therapy in breast cancer patients, noting that prior studies have not included endocrine therapy-induced alopecia.

In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.

In this case study, drospirenone use masked the diagnosis of a rare form of congenital adrenal hyperplasia, suggesting a possible delay in detecting underlying endocrinopathies.

This article reviews alopecia treatment and reports a case where hair regrew rapidly with prednisolone, but fell out again after stopping the medication; no new results are presented.